PrEP影响试验中的HIV血清转化和基因型病毒耐药性概况

IF 2.8 3区医学 Q2 INFECTIOUS DISEASES

HIV Medicine Pub Date : 2025-05-21 DOI:10.1111/hiv.70045

Andrea Cartier, Ana Milinkovic, Lisa Goodall, Borja Mora-Peris, Dana Ogaz, Adrian Palfreeman, Branca Pereira, Iain Reeves, John Saunders, Ann K Sullivan

{"title":"PrEP影响试验中的HIV血清转化和基因型病毒耐药性概况","authors":"Andrea Cartier, Ana Milinkovic, Lisa Goodall, Borja Mora-Peris, Dana Ogaz, Adrian Palfreeman, Branca Pereira, Iain Reeves, John Saunders, Ann K Sullivan","doi":"10.1111/hiv.70045","DOIUrl":null,"url":null,"abstract":"Objectives: Here we describe HIV seroconversion events in participants of the PrEP Impact trial.Methods: Of 24 268 participants, we reviewed data for the 54 who were diagnosed with HIV during the trial; 11 at baseline.Results: Incidence was low for those diagnosed pre-pandemic at 0.13 per 100 person-years, and mainly linked to low self-reported adherence. The emergence of drug resistance in participants reporting recent oral PrEP (tenofovir disoproxil maleate with emtricitabine (TDF/FTC)) exposure was low (where analysis results are available, 21% of participants who seroconverted during trial participation showed drug resistance).Conclusions: Oral PrEP TDF/FTC is an effective HIV prevention intervention. Further data are needed to assess the prevalence and impact of increasing oral PrEP TDF/FTC use on HIV resistance.","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"HIV seroconversions and genotypic viral resistance profiles in the PrEP impact trial.\",\"authors\":\"Andrea Cartier, Ana Milinkovic, Lisa Goodall, Borja Mora-Peris, Dana Ogaz, Adrian Palfreeman, Branca Pereira, Iain Reeves, John Saunders, Ann K Sullivan\",\"doi\":\"10.1111/hiv.70045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objectives: Here we describe HIV seroconversion events in participants of the PrEP Impact trial.Methods: Of 24 268 participants, we reviewed data for the 54 who were diagnosed with HIV during the trial; 11 at baseline.Results: Incidence was low for those diagnosed pre-pandemic at 0.13 per 100 person-years, and mainly linked to low self-reported adherence. The emergence of drug resistance in participants reporting recent oral PrEP (tenofovir disoproxil maleate with emtricitabine (TDF/FTC)) exposure was low (where analysis results are available, 21% of participants who seroconverted during trial participation showed drug resistance).Conclusions: Oral PrEP TDF/FTC is an effective HIV prevention intervention. Further data are needed to assess the prevalence and impact of increasing oral PrEP TDF/FTC use on HIV resistance.\",\"PeriodicalId\":13176,\"journal\":{\"name\":\"HIV Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-05-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"HIV Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/hiv.70045\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/hiv.70045","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

目的：在这里，我们描述了PrEP影响试验参与者的HIV血清转化事件。方法：在24268名参与者中，我们回顾了54名在试验期间被诊断为HIV的患者的数据；基线值为11。结果：大流行前确诊患者的发病率较低，为每100人年0.13例，主要与自我报告的依从性较低有关。报告近期口服PrEP（替诺福韦双奥proxil马来酸酯与恩曲他滨（TDF/FTC））暴露的参与者中出现耐药性的情况很低（在可获得分析结果的情况下，参与试验期间血清转化的参与者中有21%出现耐药性）。结论：口服PrEP TDF/FTC是有效的HIV预防干预措施。需要进一步的数据来评估增加口服PrEP TDF/FTC使用对艾滋病毒耐药性的流行程度和影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

HIV seroconversions and genotypic viral resistance profiles in the PrEP impact trial.

Objectives: Here we describe HIV seroconversion events in participants of the PrEP Impact trial.

Methods: Of 24 268 participants, we reviewed data for the 54 who were diagnosed with HIV during the trial; 11 at baseline.

Results: Incidence was low for those diagnosed pre-pandemic at 0.13 per 100 person-years, and mainly linked to low self-reported adherence. The emergence of drug resistance in participants reporting recent oral PrEP (tenofovir disoproxil maleate with emtricitabine (TDF/FTC)) exposure was low (where analysis results are available, 21% of participants who seroconverted during trial participation showed drug resistance).

Conclusions: Oral PrEP TDF/FTC is an effective HIV prevention intervention. Further data are needed to assess the prevalence and impact of increasing oral PrEP TDF/FTC use on HIV resistance.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

HIV Medicine 医学-传染病学

CiteScore

5.10

自引率

10.00%

发文量

167

审稿时长

6-12 weeks

期刊介绍： HIV Medicine aims to provide an alternative outlet for publication of international research papers in the field of HIV Medicine, embracing clinical, pharmocological, epidemiological, ethical, preclinical and in vitro studies. In addition, the journal will commission reviews and other feature articles. It will focus on evidence-based medicine as the mainstay of successful management of HIV and AIDS. The journal is specifically aimed at researchers and clinicians with responsibility for treating HIV seropositive patients.